Silicon Genomics is a science-focused, technology-based collaboration whose primary objective is to advance the discovery of human therapeutics by providing the scientific community with innovative technological tools designed to optimize the entire drug discovery process.
Silicon Genomics was conceived with a radical vision to revolutionize insilico drug discovery in order to benefit society by increasing the number of novel therapeutics that could be identified and brought to market more rapidly and safely.
Silicon Genomics will be a collaborative initiative of the Cloud Life Sciences Alliance and a cadre of Life Science organizations that recognize the scientific, technological and economic value of a shared, cloud-based, high performance computing capability.
A key goal of the Alliance will be to address the critical need for small, underfunded research labs that are focused on the discovery of novel therapeutics for the orphan drug market, to gain access to high-performance computing resources that would otherwise be beyond their financial means and technical capabilities.
Silicon Genomics Value Proposition
The far-reaching design objective for NeuroGen is to optimize the entire drug discovery process in order to speed analysis and increase the identification of new and innovative therapeutics. NeuroGen will revolutionize insilico drug discovery by improving not only the computational speed but the overall process by which drugs are discovered.
NeuroGen: Key Benefits
During the analysis and design phase, the first test that any requirement needs to pass is; Does it support our ultimate goal of benefiting science and society? We believe that every aspect of NeuroGen does.
We sustain a culture rooted in technological and scientific entrepreneurialism and innovation. As a science-focused and technology-based organization, Silicon Genomics will follow the science wherever it may lead, in order to provide the best insilico tools to identify causes and develop novel treatments for serious illness.